Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts rate Pyxis Oncology “Moderate Buy.” Eight of 10 analysts recommend buying the stock, while one rates it a hold and one a sell; the average 12-month price target is $7.50.
• Recent analyst actions were mixed, including a downgrade from Wall Street Zen and price-target cut by Leerink Partners, alongside new bullish coverage from Wells Fargo with a $12 target.
• Pyxis Oncology reported a quarterly loss of $0.40 per share, missing estimates by $0.05. The clinical-stage biotechnology company develops antibody-drug conjugates for cancer treatment, and institutional investors own about 39% of its shares.

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $7.50.

A number of equities analysts recently weighed in on PYXS shares. Wall Street Zen downgraded shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Leerink Partners cut their price target on shares of Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating on the stock in a research report on Thursday, July 2nd. Wells Fargo & Company started coverage on Pyxis Oncology in a report on Monday, August 3rd. They set an "overweight" rating and a $12.00 price target for the company. Wedbush started coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They issued an "outperform" rating and a $6.00 price objective for the company. Finally, Weiss Ratings downgraded Pyxis Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 30th.

Pyxis Oncology Stock Performance

NASDAQ:PYXS opened at $3.01 on Friday. Pyxis Oncology has a fifty-two week low of $1.03 and a fifty-two week high of $5.55. The company has a 50 day simple moving average of $2.56 and a two-hundred day simple moving average of $1.97. The company has a market capitalization of $190.68 million, a PE ratio of -2.13 and a beta of 1.31.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). Research analysts predict that Pyxis Oncology will post -1.19 EPS for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several institutional investors have recently added to or reduced their stakes in PYXS. Bank of America Corp DE boosted its holdings in shares of Pyxis Oncology by 20.3% during the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock worth $84,000 after buying an additional 9,062 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Pyxis Oncology during the 1st quarter worth approximately $81,000. XTX Topco Ltd bought a new stake in shares of Pyxis Oncology in the 2nd quarter valued at $40,000. Marshall Wace LLP bought a new stake in shares of Pyxis Oncology in the 2nd quarter valued at $163,000. Finally, Qube Research & Technologies Ltd lifted its position in shares of Pyxis Oncology by 128.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company's stock valued at $113,000 after acquiring an additional 57,935 shares during the period. 39.07% of the stock is owned by institutional investors and hedge funds.

About Pyxis Oncology

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source